SIHUAN PHARM (00460) announced that, following a simplified renewal negotiation with the National Healthcare Security Administration, its non-wholly owned subsidiary Xuanzhu Biotech's self-developed innovative drug Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei®) will continue to be included in the updated National Reimbursement Drug List (NRDL) for 2025, effective from January 1, 2026.

As the first and only domestically developed proton pump inhibitor in China, Anjiuwei® was approved in June 2023 for treating duodenal ulcers and first included in the NRDL in December 2023. The successful renewal of Anjiuwei® in the 2025 NRDL is expected to stabilize market sales, benefit more patients, enhance the drug's penetration rate in relevant indications, and drive long-term growth for the product.